CCL3 and infection: We have previously demonstrated that topical treatment with CCL3/MIP-1α immunomodulator reduced infection by >99% and improved healing in diabetic mice by bypassing impaired FPR signaling and restoring timely neutrophil trafficking, highlighting its potential in diabetic wound care [4].